162 related articles for article (PubMed ID: 18710351)
1. Pharmacotherapy of relapsed metastatic testicular cancer.
Kollmannsberger C; Honecker F; Bokemeyer C
Expert Opin Pharmacother; 2008 Sep; 9(13):2259-72. PubMed ID: 18710351
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Kollmannsberger C; Bokemeyer C
Curr Opin Support Palliat Care; 2008 Sep; 2(3):167-72. PubMed ID: 18685416
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Klaproth H; Kubin T; Sayer HG; Hentrich M; Welslau M; Mayer F; Kuczyk M; Spott C; Kanz L; Bokemeyer C
Br J Cancer; 2002 Sep; 87(7):729-32. PubMed ID: 12232755
[TBL] [Abstract][Full Text] [Related]
4. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update.
Koychev D; Oechsle K; Bokemeyer C; Honecker F
Int J Androl; 2011 Aug; 34(4 Pt 2):e266-73. PubMed ID: 21790652
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacotherapy for testicular germ cell cancer.
Alsdorf W; Seidel C; Bokemeyer C; Oing C
Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243
[TBL] [Abstract][Full Text] [Related]
8. [Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases].
Sun XF; Yang QY; Zhen ZJ; Xia Y; Huang ZH; Ling JY
Ai Zheng; 2006 Dec; 25(12):1529-32. PubMed ID: 17166380
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
[TBL] [Abstract][Full Text] [Related]
10. [Testicular cancer--is there an indication for adjuvant or neoadjuvant systemic therapy?].
Langenkamp S; Albers P
Urologe A; 2007 Oct; 46(10):1389-90, 1392-4. PubMed ID: 17874229
[TBL] [Abstract][Full Text] [Related]
11. [Surgery of residual masses after chemotherapy in patients with testicular cancer].
Fléchon A; Rivoire M; Berger N
Rev Prat; 2007 Feb; 57(4):389-98. PubMed ID: 17455741
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
13. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors.
Oing C; Lorch A
Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143
[TBL] [Abstract][Full Text] [Related]
14. Salvage Therapy for Patients With Germ Cell Tumor.
Rashdan S; Einhorn LH
J Oncol Pract; 2016 May; 12(5):437-43. PubMed ID: 27170693
[TBL] [Abstract][Full Text] [Related]
15. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
[TBL] [Abstract][Full Text] [Related]
16. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
17. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
[TBL] [Abstract][Full Text] [Related]
18. Dose intense chemotherapy in the management of poor prognosis and relapsed testicular cancer: experiences and controversies.
Ng K; Duncan S; Shamash J; Alifrangis C
Expert Rev Anticancer Ther; 2018 May; 18(5):431-436. PubMed ID: 29557197
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Powles T; Shamash J; Berney D; Oliver RT
Br J Cancer; 2003 Sep; 89(6):1140-1; author reply 1141-2. PubMed ID: 12966438
[No Abstract] [Full Text] [Related]
20. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
